Search

Introduction/Background: The presence of perfluorocarbon into the anterior chamber can produce endothelial damage and increased intraocular pressure. An unusual approach is presented for removal of the perfluorocarbon migrated to the anterior chamber in an aphakic patient, which remained after the refloat of the complex bag-IOL dislocated in the vitreous chamber. Methods: Case report. Results: A myopic magna patient underwent surgery for dislocation of the complex capsular bag-intraocular lens on the right eye. Pars plana vitrectomy was performed with 23 G and refloating of the complex capsular bag-lens dislocated with perfluorocarbon. A month after the surgery procedure, a level of 1.5 mm of perfluorocarbon was noted in the anterior chamber. To remove it, in the operating room, the patient was positioned semi-sitting, in a 45 degrees angle to the horizontal. The knees were flexed and the feet rested on the ground. The surgeon with the microscope was placed in front of the patient to perform the procedure: a main incision was done at IV and another accessory incision at VIII, viscoelastic was injected into the anterior chamber and the perfluorcarbon was completely removed with manual irrigation-aspiration. Finally, saline solution was used to hydrate the corneal incisions. Conclusions: The semi-sitting position of the patient is a useful way to reach the perfluorocarbon located in the bottom of the anterior chamber, otherwise the supine position cause its displacement to the posterior chamber. Thus, we think it's a good option to manage this vitreorretinal surgery complication allowing the complete perfluorocarbon removal with a simple surgery. Acknowledgements: None. [ABSTRACT FROM AUTHOR]

Introduction/Background: Hallervorden-Spatz syndrome is an autosomal recessive neurodegenerative disorder with brain iron accumulation. The classical form has a progressive early onset in infancy that results in the presence of extrapyramidal symptoms and retinitis pigmentosa (RP). The clinical symptoms and signs in RP include nyctalopia and peripheral visual field reduction. Cystoid macular oedema (CMO) can occasionally occur in RP. Pathogenesis of CMO remains unclear and no gold-standard treatments or protocols have established yet. Methods: Case report. Patient monitored with OCT imaging and treated with topic brinzolamide 10 mg/ml and topical nepafenac 1 mg/ml. Results: A 10 year-old female, diagnosed with Hallervorden- Spatz disease, was derived to the Ophthalmology service from Paediatrics with a progressive vision loss. During exploration, bestcorrected visual acuity (BCVA) was 0.2 in both eyes. Macular OCT was performed and a bilateral CMO was found. Bone spicule pigmentation was observed in periphery without further pathological findings. She was diagnosed with RP. Topic brinzolamide was prescribed and there was vision improvement with bilateral reduction of the CMO. Two months later, BCVA deteriorated although CMO diminished; treatment with brinzolamide was maintained and a topical non-steroidal anti-inflammatory (nepafenac) was added. After three months of double therapy, her BCVA was 0.9 in both eyes and the CMO had considerably reduced. Two months later, the CMO was prominent again and her BCVA had decreased again. Due to the evolution with topical treatment, the patient was finally derived to a children's referral hospital where she can be treated more aggressively (intravitreal and/or subtenon triamcinolone acetonide injection, intravitreal dexamethasone implant or intravitreal anti-VEGF injection). Conclusions: There is no specific treatment to arrest or reverse the photoreceptor degeneration, but complications can be managed in diverse ways. Since a protocol to treat CMO in RP is lacking, a gradually aggressive treatment steps should be followed. Acknowledgements: To Ana Montoliu Antón, Francisco Ramos Martí, Soledad Peña, María Redón Soriano and especially Luis León Ibáñez. [ABSTRACT FROM AUTHOR]